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Autoanti-C in a patient with primary sclerosing 
cholangitis and autoimmune hemolytic anemia: 
a rare presentation
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Case RepoRt
Primary sclerosing cholangitis (PSC) is rarely associated with 
autoimmune hemolytic anemia (AIHA), and the presence of 
specific autoantibodies has not been reported previously. We 
present a unique case report of PSC associated with AIHA 
implicating autoanti-C. A 17-year-old girl was admitted to 
our hospital with PSC along with AIHA. Her blood sample 
demonstrated a positive direct antiglobulin test and a positive 
autocontrol in the antihuman globulin phase, confirming the 
patient had warm-reactive AIHA. Further testing showed the 
possibility of anti-C. The patient’s Rh phenotype was C+D+E–c–
e+. Further testing with select cells, serial alloadsorption, and an 
elution confirmed anti-C specificity. The patient was transfused 
with two C–, crossmatch-compatible packed red blood cell units. 
The patient’s hemoglobin level and general condition showed 
improvement. This unique case report shows PSC associated 
with AIHA caused by autoanti-C. Usually, warm AIHA presents 
with a panreactive pattern, and it is difficult to find compatible 
blood. In this rare case, we could determine the specific 
antibody; efforts should always be made in cases of AIHA to 
identify the specificity of autoantibody. Immunohematology 
2016;32:104–107.
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Autoimmune hemolytic anemia (AIHA) is an uncommon 
condition, with prevalence of approximately 1.7 per 100,000 
individuals.1 Usually, these antibodies are panreactive, but 
they may rarely exhibit specific reactivity against red blood 
cell (RBC) antigens. Diagnosis of AIHA is based mainly on 
the direct antiglobulin test (DAT). AIHA can be classified as 
warm type (optimal reactivity at 37°C), cold type (optimal 
reactivity at 4°C), or both, classified as mixed-type AIHA.2 
On the basis of the presence or absence of underlying etiology, 
AIHA is further divided into primary (idiopathic) or secondary 
(secondary to lymphoproliferative disorder, autoimmune 
diseases, drugs, and non-hematological malignancies).1 
Primary sclerosing cholangitis (PSC) is rarely associated with 
AIHA, and the presence of a specific autoantibody has not 
been reported previously.3,4 We present a unique case report of 
PSC associated with AIHA caused by autoanti-C. 
Case Report
A 17-year-old girl was admitted to our hospital with chief 
complaints of abdominal pain in the upper-right quadrant, 
breathlessness, jaundice, fatigue, weakness, and falling 
hemoglobin for the past 2 weeks. She had similar episodes in 
the past; the first at the age of 5 years (which resolved within 
10–12 days), and again, 16 months later, for which she was 
treated with steroids and supportive therapy. There was no 
history of RBC transfusions, a fact that was reconfirmed 
in view of the long history of the disease. Her family stated 
that previous episodes had been mild. Family history was 
not relevant to the current disorder. She had no history of 
pregnancy or transplantation. On physical examination, she 
had mild hepatosplenomegaly. Lab tests revealed a hemoglobin 
(Hb) of 5.8 g/dL (normal range 12–16 g/dL) and a hematocrit 
of 18.6% (normal range 36–48%). Liver function tests revealed 
a total bilirubin of 2.3 g/dL (normal range 0.3–1.9 mg/dL) and 
increased serum alkaline phosphatase, up to 152 IU/L (normal 
range 44–147 IU/L).
On immunofluorescence, her anti-nuclear antibody test was 
positive; tests for anti-neutrophilc cytoplasmic antibodies, anti-
smooth muscle antibodies, and anti-mitochondrial antibodies 
were all negative. Serum IgG4 levels were within the normal 
range. Computed tomography of the abdomen showed diffuse 
fusiform dilatation and narrowing of the common bile duct 
with multiple areas of focal fusiform dilatation in intrahepatic 
biliary radicles, with attenuation in both lobes of the liver. 
Imaging findings were indicative of PSC. Colonic biopsies 
were done from multiple sites to rule out ulcerative colitis; on 
pathological examination, these were largely unremarkable, 
with no evidence of inflammatory bowel disease.
Materials and Methods
The patient’s blood type was group O, D+, her DAT 
was positive with 4+ reactivity using column agglutination 
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technique (CAT) with an antihuman globulin (AHG) gel card 
that is IgG-specific (DiaMed, Cressiers/Morat, Switzerland). 
Her autocontrol was negative at 4°C, room temperature, 
and 37°C, but showed 2+ reactivity in the AHG phase on 
CAT gel card, thus confirming this patient as having warm-
reactive AIHA. Further testing was performed to identify the 
autoantibody. 
First, the patient’s serum was tested against a three-cell 
antibody screening panel, which showed reactivity in one cell 
in the AHG phase, and the autocontrol was positive. An 11-
cell identification panel was used that showed the possibility of 
the antibody being of anti-C specificity (Table 1). The patient’s 
Rh phenotype was performed showing C+D+E–/c–e+. For 
confirmation, three samples of C+ RBCs and three samples 
of C– RBCs were tested against the patient’s serum (rule 
of 3). The C– cells were compatible and the C+ cells were 
incompatible with the patient’s serum, confirming the 
specificity as anti-C. For further confirmation, we performed 
serial alloadsorptions with C+ RBCs; the adsorbed patient 
serum showed no agglutination with the panel cells, which 
included C+ RBCs. Furthermore, before alloadsorption, the C+ 
allogeneic RBCs were DAT– (control), and after alloadsorption, 
they became DAT+, thus confirming adsorption of anti-C 
(Table 2). We performed an acid elution (Gamma ELU-KIT, 
Immucor Medizinische Diagnostik, Rödermark, Germany) of 
these alloadsorbed RBCs, and the eluate showed agglutination 
with C+ cells and no agglutination with C– cells (control). 
This testing confirmed the presence of autoanti-C of warm 
type reacting at the AHG phase only. An eluate of the patient’s 
RBCs was made and tested against the identification panel. 
The results showed a nonspecific pattern: stronger reactivity 
with all C+ RBCs, but weak reactivity with some C– RBCs.
As the patient’s hemoglobin was continuously falling, 
she was treated with immunosuppressants (azathioprine 
and steroids); the next day, she was transfused with two 
C–, crossmatch-compatible units of packed RBCs with no 
untoward reactions. Rh-phenotype matching was not done, 
since we have a small inventory, and it would not have been 
possible. The patient’s Hb showed an immediate rise from 5.8 
to 9.6 g/dL and then dropped to 8.5 g/dL the next day; her 
general condition improved. Her Hb was maintained at this 
Autoanti-C in a patient with PSC
Table 1. Reactivity of patient’s serum with screening cells and identification panel cells
Screening cells
Rh-hr Lewis MNS P Kell Duffy Kidd Results
Cell No. RhType D C c E e Lea Leb M N S s P1 K k Fya Fyb Jka Jkb LISS/AHG
1 R1wR1 + + 0 0 + + 0 + 0 + + + 0 + 0 + + + 2+
2 R2R2 + 0 + + 0 0 + + + + 0 + 0 + + 0 0 + Neg
3 rr 0 0 + 0 + 0 + 0 + 0 + 0 + + + 0 + 0 Neg
Identification panel cells
1 R1wR1 + + 0 0 + 0 + + + 0 + 0 0 + + 0 + 0 2+
2 R1R1 + + 0 0 + + 0 0 + 0 + 0 + + 0 + + + 2+
3 R2R2 + 0 + + 0 0 + + 0 + 0 + 0 + + + 0 + Neg
4 r'r 0 + + 0 + 0 + + + + 0 + 0 + + 0 + 0 2+
5 r"r 0 0 + + + 0 + 0 + 0 + + 0 + + 0 + + Neg
6 rr 0 0 + 0 + + 0 + 0 + 0 0 + + 0 + + 0 Neg
7 rr 0 0 + 0 + 0 0 0 + 0 + + 0 + + + + 0 Neg
8 R0r + 0 + 0 + 0 + + + 0 + + 0 + 0 0 + 0 Neg
9 rr 0 0 + 0 + + 0 + 0 + 0 + 0 + 0 + 0 + Neg
10 rr 0 0 + 0 + + 0 0 + 0 + + 0 + + 0 + 0 Neg
11 rr 0 0 + 0 + 0 0 + 0 + + 0 0 + + 0 0 + Neg
Autocontrol                   2+
LISS = low-ionic-strength saline; AHG = antihuman globulin; Neg = negative (no agglutination).











R1R1 (D+C+E–c–e+) 2+ Negative 2+
R2R2 (D+C–E+c+e–) Negative Negative Negative
rr (D–C–E–c+e+) Negative Negative Negative
DAT of alloadsorbed RBCs NT 2+ Negative
RBC = red blood cell; DAT = direct antiglobulin test; NT = not tested.
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level with minor fluctuations for 1 month. The patient was lost 
to follow-up beyond that. No more transfusions were required 
during the rest of her hospital stay.
Discussion
PSC is an uncommon condition characterized by chronic 
progressive inflammatory fibrosis of the biliary tract, which 
can lead to biliary cirrhosis, portal hypertension, and liver 
failure.5,6 The recommendation for patients younger than 
25 years of age with PSC is to perform additional testing for 
autoimmune hepatitis. The prevalence of autoimmune hepatitis 
in PSC patients ranges from 1.4 percent to 17 percent.7 Patients 
with PSC should also be tested for serum levels of IgG4, since 
a subset of these patients have markedly high levels of IgG4 
(>140 mg/dL).8 Corticosteroids and other immunosuppressant 
agents are more effective in patients with IgG4-related PSC 
than in those with non–IgG4-related PSC. In our reported 
case, the patient’s IgG4 levels were in the normal range, but 
because of the autoimmune association, she was started on 
immunosuppressive therapy.
In the literature, a few cases have been reported showing 
an association between PSC and AIHA, not associated with 
inflammatory bowel disease, as in our case.9,10 A study done 
by Vaglio et al. showed that out of 100 AIHA cases studied, 
54 percent were associated with an underlying disorder; of 
these secondary AIHA cases, autoimmune disorders were 
most frequent, and the majority (64%) of antibodies detected 
were of the warm-reactive type.11 In this case, similar findings 
were observed, since the autoantibody showed reactivity only 
at 37°C in the AHG phase.
Detection of the specificity of autoantibody is usually 
not possible, since most cases show a panreactive pattern 
with antibody identification cell panels. A few cases of 
autoantibodies against the Rh blood group system (anti-E, 
anti-c, anti-D, anti-e) have been reported in the past with a 
specific autoantibody pattern from cell identification panels.12 
To the best of our knowledge, a confirmed case of autoanti-C 
has not been reported until now, although it was suspected 
in two cases in which autoanti-C-mimicking alloantibodies 
had been reported previously, but phenotyping identified the 
patients’ RBCs as C–.12,13 Our case is unique because PSC was 
associated with AIHA caused by autoanti-C.
Blood transfusion support for these patients is a 
challenging task. Extensive immunohematological workups 
are required, and even then, the results are often inconclusive. 
When the antigen panel shows panreactivity and compatible 
blood is not available, transfusion should not be withheld if 
the patient is in critical condition and requires an urgent 
transfusion. Autoadsorption should be done to rule out the 
presence of alloantibodies in the adsorbed serum; if antibodies 
are detected, then antigen-negative RBCs may be transfused. 
In patients who are negative for alloantibodies, phenotype-
matched blood may be transfused to prevent the development 
of alloantibodies.14 In rare cases, when it is possible to identify 
the autoantibody, antigen-negative RBCs are the therapy of 
choice, as illustrated in this case.
Acknowledgments
The authors thank Dr. Pritesh Rajani and Mr. Pankaj Jain 
for their scientific and technical input in writing this report.
References
 1. Eaton WW, Rose NR, Kalaydjian A, Pedersen MG, Mortensen 
PB. Epidemiology of autoimmune diseases in Denmark. J 
Autoimmun 2007;29:1–9.
 2. Leger RM. The positive direct antiglobulin test and immune 
mediated hemolysis. In: Fung MK, Grossman BJ, Hillyer CD, 
Westhoff CM, eds. AABB technical manual. 18th ed. Bethseda, 
MD: AABB, 2014;439.
 3. Moeller DD. Sclerosing cholangitis associated with autoimmune 
hemolytic anemia and hyperthyroidism. Am J Gastroenterol 
1985;80:122–5.
 4. Baker SS, Compton CC. A 17-year-old boy with autoimmune 
hemolytic anemia and abnormal liver function. N Engl J Med 
1991;324:180–8.
 5. Wiesner RH, LaRusso NF. Clinicopathologic features of the 
syndrome of primary sclerosing cholangitis. Gastroenterology 
1980;79:200–6.
 6. Chapman RW, Arborgh BA, Rhodes JM, et al. Primary 
sclerosing cholangitis: a review of its clinical features, 
cholangiography, and hepatic histology. Gut 1980;21:870–7.
 7. Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary 
sclerosing cholangitis. Lancet 2013;382:1587–99.
 8. Mendes FD, Jorgensen R, Keach J, et al. Elevated serum IgG4 
concentration in patients with primary sclerosing cholangitis. 
Am J Gastroenterol 2006;101:2070–5.
IMMUNOHEMATOLOGY, Volume 32, Number 3, 2016 107
Autoanti-C in a patient with PSC
 9. Moeller DD. Sclerosing cholangitis associated with autoimmune 
hemolytic anemia and hyperthyroidism. Am J Gastroenterol 
1985;80:122–5.
 10. Salagre KD, Sahay RN, Patil A, Joshi A, Shukla A. Leukemoid 
reaction, a rare manifestation of autoimmune hemolytic 
anemia in a case of small duct primary sclerosing cholangitis. J 
Assoc Physicians India 2013;61:494–5.
 11. Vaglio S, Arista MC, Perrone MP, et al. Autoimmune hemolytic 
anemia in childhood: serologic features in 100 cases. 
Transfusion 2007;47:50–4.
 12. Issitt PD, Pavone BG. Critical re-examination of the specificity 
of auto-anti-Rh antibodies in patients with a positive direct 
antiglobulin test. Br J Haematol 1978;38:63–74.
 13. Weber J, Caceres VW, Pavone BG, Issitt PD. Allo-anti-C in a 
patient who had previously made an autoantibody mimicking 
anti-C. Transfusion 1979;19:216–8.
 14. Petz LD. A physician’s guide to transfusion in autoimmune 
haemolytic anaemia. Br J Haematol 2004;124:712–6.
Meenu Bajpai, MD, Additional Professor (corresponding author), 
Department of Transfusion Medicine, Institute of Liver & Biliary 
Sciences, Sector D-1, Vasant Kunj, New Delhi 110070, India, 
meenubajpai@hotmail.com; Ashish Maheshwari, MD, Senior 
Resident, Department of Transfusion Medicine; Shruti Gupta, MD, 
Senior Resident, Department of Transfusion Medicine; Chhagan 
Bihari, MD, Associate Professor, Department of Pathology, Institute 
of Liver & Biliary Sciences, New Delhi, India.
Immunohematology is on the Web!
www.redcross.org/about-us/publications/
immunohematology
For more information, send an e-mail to  
immuno@redcross.org.
For information concerning the National Reference 
Laboratory for Blood Group Serology, including the American 
Rare Donor Program, contact Sandra Nance, by phone at 
(215) 451-4362, by fax at (215) 451-2538, or by e-mail at 
Sandra.Nance@redcross.org.
